Oculis’ Post

As per a large study published in Ophthalmology Retina, it was found there was no substantially different relative risk for kidney failure between those who received #ranibizumab, #bevacizumab, or #aflibercept. This study reviewed data from 37,189 patients who received ranibizumab, 39,447 who received aflibercept, and 163,611 who received bevacizumab. Practicing #ophthalmologists and #nephrologists should be aware of the risk for #kidney failure among patients receiving intravitreal anti-VEGF medications. In addition, there is little empirical evidence to preferentially choose among the specific intravitreal anti-#VEGF agents. #retina #injection #intraocular #intravitreal #AMD #DME #DR https://bit.ly/4aPzJMG Pic (c) ASRS

🔍 Promising findings emerge regarding individualized dosing of faricimab (Vabysmo, Roche) every 16 weeks, sustaining robust outcomes in neovascular #AMD patients for 2 years. Dr. Varun Chaudhary shares key insights from the TENAYA and LUCERNE trials, highlighting the personalized treat-and-extend strategy. Results showcase compelling visual gains and reduced treatment frequency compared to aflibercept. This data suggests promising implications for long-term #AMDmanagement 👉 Find out more in this article from Ophthalmology Times Europe by lynda charters #Ophthalmology #HealthcareInnovation #EyeHealth #EyeSurgery #Biotech #Medtech #Lifescience Hattie Jean H. Emily Kaiser Maharjan

Findings from a retrospective cohort study published in JAMA Ophthalmology suggest that patients with PDR treated with PRP first then subsequent anti-VEGF injection are more likely to undergo PPV for VH and TRD compared with matched patients treated with anti-VEGF agents first followed by PRP. The authors of this publication, Amer Alsoudi, MD; Karen Wai, MD; Euna Koo, MD; Ravi Parikh MD MPH,; Prithvi Mruthyunjaya, MD,MHS; and Ehsan Rahimy, MD, suggest that considering their study was retrospective, further investigations are needed to determine if the order of PRP and anti-VEGF injections should be considered when treating patients with PDR. https://bit.ly/3XHLvVL Representative picture: PDR with TRD (c) ASRS Image Bank

Breaking barriers in glaucoma treatment! Celanese Corporation and Glaukos Corporation join forces to introduce iDose(R) TR, a game-changer in sustained drug release for better patient outcomes. Discover how this innovative solution is reshaping ophthalmology! #GlaucomaInnovation #CelaneseImpact #MedicalAdvancements #EyeCare #TidbitThursday

Read this exciting article where we explore GLP-1 receptor analogs and their potential role in the treatment of glaucoma. 

🔬 Exploring the landscape of bispecific agents in ophthalmology reveals exciting advancements and potential treatments for #wetAMD and DME. Learn about the promising developments and ongoing research in this rapidly evolving field. 👉 Find out more in this article from Healio by Jennifer R. Southall #AMD #Ophthalmology #HealthcareInnovation #EyeHealth #EyeSurgery #Biotech #Medtech #Lifescience

Decreasing vitamin A dimerization may be a promising treatment avenue for treating geographic atrophy (#GA). In his presentation at #Retina Subspecialty Day at the American Academy of Ophthalmology meeting, alex melamud, MD, unveiled topline results from the phase 3 SAGA study investigating the efficacy, safety and pharmacokinetics of oral #gildeuretinol, a form of deuterated vitamin A, in patients with GA. The randomized, double-masked, placebo-controlled study assigned a total of 198 patients to treatment with gildeuretinol (135 patients) or placebo (43 patients), 70% of whom completed the study. The primary efficacy endpoint was the rate of lesion growth at 24 months, with secondary endpoints including low-luminance visual acuity and best corrected VA. A pre-specified sensitivity analysis demonstrated a statistically significant 15.3% reduction in lesion growth rate from 6 to 24 months. Patients treated with gildeuretinol also saw a reduced loss of vision compared with those in the placebo cohort, with 4.4 fewer ETDRS letters lost overall. https://bit.ly/3Yyn8di Pic (c) Retinal Physician #ophthalmology #optometry #vision #AMD #dryAMD #MacularDegeneration #drusen

We are pleased to present our recent publication regarding one of the recent octa imaging findings, SSPIM of diabetic macular edema and its  implications on treatment response, published in  one of the Q2 journals (Graefes Archive of Ophthalmology). Focus on additional DME biomarkers and their influence on  the course of the disease. Here is the full text link if you are interested in !!! https://lnkd.in/dkEtTCUX #ankaratıpfakültesi #ankaratıpgöz #ankaraüniversitesi #ankaratıp #retinalimaging #opticcoherencetomographyangiography #oct #diabeticretinopathy #retinalimaging #diabeticmacularedema #biomarker

Reminder! You still have time to sign up for our webinar on "Addressing Ophthalmology Clinical Trial Design and Effective Data Monitoring Committee Strategies" happening at 1:30pm CEST (EU-Central). Don't miss out! Register here: https://hubs.la/Q02h5Bv50 #Ophthalmology #Biostatistics #ClinicalTrials #CROpartner #DataMonitoringCommittees

Lipid hard exudates can be particularly challenging in our patients with diabetic macular edema. A big thank you to Healio | Ocular Surgery News and Anthony DeFino and Eamon Dreisbach for covering our research looking at the efficacy of #faricimab in resolving hard exudates in the pivotal #yosemite and #rhine trials of patients with #DiabeticMacularEdema and #DiabeticRetinopathy. Kara Gibson PhD Manuel Amador, MD Florie Mar, PhD https://lnkd.in/ga-y9GHG